UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,427,415 B2

APPLICATION NO.: 10/684859

DATED : September 23, 2008

INVENTOR(S) : Scharp et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Page 2, Column 2, Entry 5, (Foreign Patent Documents) "ES 210472T T3" should be changed to --ES 2104727T T3--

Page 2, Column 2, Line 58, (Other Publications) "Procine Pancreatic" should be changed to --Porcine Pancreatic--

Column 12, Line 51, "thoionine, riboflavin" should be changed to --thionine, riboflavin--

Column 13, Line 5, "omithine, histidine" should be changed to --ornithine, histidine--

Column 13, Line 58, "omithine, histidine" should be changed to --ornithine, histidine--

Column 15, Line 50, "at 285 days" should be changed to --at 285 days.--

Column 17, Line 67, "cells or tissue" should be changed to --cells or tissue.--

Column 21, Line 67, "loss of weight" should be changed to --loss of weight.--

Column 22, Line 2, "insulin granules" should be changed to --insulin granules.--

Column 29, Line 2, "omithine, histidine" should be changed to --ornithine, histidine--

UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO.

: 7,427,415 B2

Page 2 of 2

APPLICATION NO.: 10/684859

DATED

: September 23, 2008

INVENTOR(S)

: Scharp et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 31, Line 25, "CaC12 and" should be changed to -- CaCl2 and--

Column 34, Line 14, "post-implantation" should be changed to --post-implantation.--

Column 41, Line 21, "cylosporinen administration" should be changed to --cyclosporine administration--

Column 51, Line 33, "and TBMX insulin" should be changed to -- and IBMX insulin-

Column 54, Line 45, "encapsulated cells" should be changed to --encapsulated cell--

Column 54, Line 50, "weight of between" should be changed to --weight between--

Column 55, Line 13, "the polymerizable" should be changed to -- the covalently polymerizable--

Column 55, Line 33, "omithine, histidine" should be changed to --ornithine, histidine--

Column 56, Line 8, "a polyethylene" should be changed to --a covalently linked polyethylene--

Signed and Sealed this

Nineteenth Day of May, 2009

John Ooll

JOHN DOLL Acting Director of the United States Patent and Trademark Office